The Breast International Group, the European Organization for Research and Treatment of Cancer and the Alliance Foundation Trials groups are collaborating with Sanofi to initiate a pivotal trial of an oral selective estrogen receptor degrader (SERD) in the adjuvant setting.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
